• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishDashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI employees
    Legal
    Terms of usePrivacy policyCookie policy

    Vaxart Inc filed SEC Form 8-K: Submission of Matters to a Vote of Security Holders, Regulation FD Disclosure, Financial Statements and Exhibits

    6/2/25 4:56:07 PM ET
    $VXRT
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care
    Get the next $VXRT alert in real time by email
    vxrt20250602_8k.htm
    false 0000072444 0000072444 2025-06-02 2025-06-02
     
    UNITED STATES
    SECURITIES AND EXCHANGE COMMISSION
    Washington, D.C. 20549
     
    FORM 8-K
     
    CURRENT REPORT
    Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934
     
    Date of Report (Date of earliest event reported): June 2, 2025
     
    Vaxart, Inc.
    (Exact name of registrant as specified in its charter)
     
     
    Delaware
     
    001-35285
     
    59-1212264
    (State or other jurisdiction of incorporation)
     
    (Commission File Number)
     
    (IRS Employer Identification No.)
     
    170 Harbor Way, Suite 300, South San Francisco, California
     
    94080
    (Address of principal executive offices)
     
    (Zip Code)
     
     
    Registrant’s telephone number, including area code: (650) 550-3500
     
     
    Not Applicable
    (Former name or former address, if changed since last report.)
     
    Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
     
    ☐
    Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
     
    ☐
    Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
     
    ☐
    Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
     
    ☐
    Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
     
    Securities registered pursuant to Section 12(b) of the Act:
     
    Title of each class
     
    Trading symbol
     
    Name of each exchange on which registered
    Common Stock, $0.0001 par value
     
    VXRT
     
    The Nasdaq Capital Market
     
    Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).
     
    Emerging Growth Company ☐
     
    If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐
     
     

     
     
    Item 5.07
    Submission of Matters to a Vote of Security Holders.
     
    On June 2, 2025, Vaxart, Inc. (the “Company”) reconvened the Company’s 2025 annual meeting of stockholders (the “Annual Meeting”). Proxies had been submitted by stockholders representing approximately 67.89% of the shares of the Company’s common stock outstanding and entitled to vote, which constituted a quorum.
     
    The four proposals listed in the proxy statement (as supplemented, the “Proxy Statement”) filed with the U.S. Securities and Exchange Commission (the “SEC”) on April 10, 2025, for the Annual Meeting were not voted on at the Annual Meeting because the Company’s board of directors (the “Board of Directors”) believes that it is important to provide stockholders additional time within which to vote, and therefore the Company adjourned the Annual Meeting. In particular, there were insufficient votes present at this Annual Meeting to approve Proposal No. 2, which is the proposal to adopt and approve an amendment to the Company’s Restated Certificate of Incorporation to allow the Company’s Board of Directors, if they deem necessary, to effect a reverse stock split of issued shares of the Company’s common stock into a lesser number of shares. Because the Board of Directors continues to believe that Proposal No. 2 is advisable and in the best interests of the Company’s stockholders, the Company adjourned this Annual Meeting in order to allow additional time for its stockholders to vote and to solicit additional votes in favor of such proposal.
     
    The reconvened Annual Meeting will be held on Friday, June 13, 2025 at 8:30 a.m. Pacific Time through live webcast of the meeting, as described on the Proxy Statement and proxy card or in the instructions that accompanied the proxy materials to the Company’s stockholders.
     
    During the period of the adjournment, the Company will continue to solicit votes from its stockholders with respect to the proposals for the Annual Meeting. Stockholders who have already voted do not need to recast their votes. Proxies previously submitted in respect of the Annual Meeting will be voted at the adjourned Annual Meeting unless properly revoked in accordance with the procedures described in the Proxy Statement.
     
    The close of business on March 26, 2025 will continue to be the record date for the determination of stockholders of the Company entitled to vote at the Annual Meeting.
     
    Forward-Looking Statements
     
    Statements contained or incorporated by reference in this Current Report on Form 8-K (this “Form 8-K”) which relate to other than strictly historical facts, such as statements about the Company’s plans and strategies are forward-looking statements. The words “believe,” “expect,” “intend,” “anticipate,” “estimate,” “project,” and similar expressions identify forward-looking statements that speak only as of the date of this Form 8-K. Investors are cautioned that such statements involve risks and uncertainties that could cause actual results to differ materially from historical or anticipated results due to many factors including, but not limited to, the Company’s continuing operating losses, uncertainty of market acceptance, reliance on third party manufacturers, accumulated deficit, future capital needs, uncertainty of capital funding, dependence on limited product line and distribution channels, competition, limited marketing and manufacturing experience, and other risks detailed in the Company’s most recent Annual Report on Form 10-K and other filings with the SEC. The Company undertakes no obligation to publicly update or revise any forward-looking statements.
     
    Additional Information and Where to Find It
     
    In connection with the Annual Meeting of stockholders, the Company filed with the SEC a definitive Proxy Statement of which notice was mailed to the Company’s stockholders as of the record date for the Annual Meeting of stockholders. STOCKHOLDERS AND OTHER INTERESTED PERSONS ARE ADVISED TO READ THE DEFINITIVE PROXY STATEMENT, AS WELL AS ALL AMENDMENTS AND SUPPLEMENTS THERETO, BECAUSE IT CONTAINS IMPORTANT INFORMATION ABOUT THE MATTERS BEFORE THE STOCKHOLDERS AT THE ANNUAL MEETING. The Company’s stockholders may also obtain copies of the Proxy Statement, the annual report to stockholders and all other relevant documents filed or that will be filed with the SEC in connection with the Annual Meeting, without charge, once available, at the SEC’s website at http://www.sec.gov or by directing a request to: Vaxart, Inc., 170 Harbor Way, Suite 300, South San Francisco, California.
     
     

     
     
    Participants in the Solicitation
     
    The Company and certain of its respective directors, executive officers, and other members of management and employees may be deemed participants in the solicitation of proxies of the Company’s stockholders in connection with the Annual Meeting. STOCKHOLDERS AND OTHER INTERESTED PERSONS MAY OBTAIN, WITHOUT CHARGE, MORE DETAILED INFORMATION REGARDING THE DIRECTORS AND OFFICERS OF THE COMPANY IN ITS ANNUAL REPORT ON FORM 10-K FOR THE FISCAL YEAR ENDED DECEMBER 31, 2024, WHICH WAS FILED WITH THE SEC ON MARCH 20, 2025 AND NOTICE OF HOW TO ACCESS SUCH ANNUAL REPORT WAS PROVIDED TO STOCKHOLDERS ALONG WITH THE NOTICE OF THE PROXY STATEMENT.
     
    Item 7.01
    Regulation FD Disclosure.
     
    On June 2, 2025, the Company issued a press release announcing the adjournment of the Annual Meeting. A copy of the press release is attached hereto as Exhibit 99.1.
     
    The information in this Item 7.01, and Exhibit 99.1 attached hereto, is being furnished and shall not be deemed “filed” for the purposes of Section 18 of the Securities Exchange Act of 1934, as amended, or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended, regardless of any general incorporation language in such filing.
     
    Item 9.01
    Financial Statements and Exhibits.
     
    (d) Exhibits
     
    Exhibit
     
    Description
         
    99.1
     
    Press Release, dated June 2, 2025.
         
    104
     
    Cover Page Interactive Data File (embedded within Inline XBRL document).
     
     

     
     
    SIGNATURES
     
    Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
     
    Date: June 2, 2025
    VAXART, INC.
         
     
    By:
    /s/ Steven Lo
       
    Steven Lo
       
    President and Chief Executive Officer
     
     
    Get the next $VXRT alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $VXRT

    DatePrice TargetRatingAnalyst
    8/15/2024$4.00Outperform
    Oppenheimer
    12/29/2021$13.00 → $12.00Buy
    Jefferies
    11/2/2021$15.00Overweight
    Cantor Fitzgerald
    6/30/2021$13.00 → $9.00Buy → Neutral
    B. Riley Securities
    6/29/2021$13.00 → $9.00Buy → Neutral
    B. Riley Securities
    6/24/2021$13.00Buy
    Jefferies
    More analyst ratings

    $VXRT
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Chief Financial Officer Grasman Jeroen Nicolaas was granted 350,000 shares (SEC Form 4)

      4 - Vaxart, Inc. (0000072444) (Issuer)

      5/20/25 10:45:14 AM ET
      $VXRT
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • SEC Form 3 filed by new insider Grasman Jeroen Nicolaas

      3 - Vaxart, Inc. (0000072444) (Issuer)

      5/20/25 10:43:43 AM ET
      $VXRT
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • President, Chief Exec Officer Lo Steven bought $49,000 worth of shares (100,000 units at $0.49) (SEC Form 4)

      4 - Vaxart, Inc. (0000072444) (Issuer)

      5/19/25 6:49:39 PM ET
      $VXRT
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    $VXRT
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • Vaxart Announces Adjournment of Annual Meeting of Stockholders

      Meeting adjourned to June 13, 2025 at 8:30 a.m. Pacific Time Vaxart encourages all stockholders of record on March 26, 2025 who have not yet voted to do so by 11:59 p.m. Eastern Time on June 12, 2025 Leading Independent Proxy Advisory Firms, ISS and Glass Lewis, Support Proposal #2 SOUTH SAN FRANCISCO, Calif., June 02, 2025 (GLOBE NEWSWIRE) -- Vaxart, Inc. (NASDAQ:VXRT) ("Vaxart" or the "Company") announced today that its 2025 annual meeting of stockholders (the "Annual Meeting") has been adjourned to Friday, June 13, 2025 at 8:30 a.m. Pacific Time with respect to all proposals described in Vaxart's definitive proxy statement filed with the U.S. Securities and Exchange Commission (the "

      6/2/25 4:20:08 PM ET
      $VXRT
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Vaxart to Participate at the Jefferies Global Healthcare Conference on June 5, 2025

      SOUTH SAN FRANCISCO, Calif., May 29, 2025 (GLOBE NEWSWIRE) -- Vaxart, Inc. (NASDAQ:VXRT), a clinical-stage biotechnology company developing a range of oral recombinant pill vaccines based on its proprietary delivery platform, today announced that members of the management team will participate in a fireside chat at the Jefferies Global Healthcare Conference on Thursday, June 5, 2025 at 2:00 PM ET. A live webcast of the fireside chat will be available on the Company's website at www.vaxart.com or by clicking here. A replay of the fireside chat will be available for 30 days following the conclusion of the event. Investors interested in meeting with management during the conference may

      5/29/25 4:05:00 PM ET
      $VXRT
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Vaxart's Founder and Chief Scientific Officer Provides Video Update to Stockholders

      Dr. Sean Tucker, Founder and CSO of Vaxart, Urges Stockholders to Vote FOR Reverse Stock Split Proposal by 11:59 p.m. Eastern Time on June 1, 2025 Company Corrects Record on Common Misconceptions Regarding the Reverse Stock Split Proposal SOUTH SAN FRANCISCO, Calif., May 29, 2025 (GLOBE NEWSWIRE) -- Vaxart, Inc. (NASDAQ:VXRT) (the "Company" OR "Vaxart") today announces a video update for stockholders by Dr. Sean Tucker. The video is available on Vaxart's investor relations website at investors.vaxart.com. In the video, Dr. Tucker urges stockholders to vote FOR Proposal No. 2, which grants the Board of Directors authority to implement a reverse split that would enable Vaxart regain compli

      5/29/25 8:00:20 AM ET
      $VXRT
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    $VXRT
    SEC Filings

    See more
    • Vaxart Inc filed SEC Form 8-K: Submission of Matters to a Vote of Security Holders, Regulation FD Disclosure, Financial Statements and Exhibits

      8-K - Vaxart, Inc. (0000072444) (Filer)

      6/2/25 4:56:07 PM ET
      $VXRT
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • SEC Form DEFA14A filed by Vaxart Inc

      DEFA14A - Vaxart, Inc. (0000072444) (Filer)

      5/29/25 2:58:48 PM ET
      $VXRT
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • SEC Form PRE 14A filed by Vaxart Inc

      PRE 14A - Vaxart, Inc. (0000072444) (Filer)

      5/29/25 10:14:08 AM ET
      $VXRT
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    $VXRT
    Financials

    Live finance-specific insights

    See more
    • Vaxart Provides Business Update and Reports First Quarter 2025 Financial Results

      Actively screening for the 10,000 participant portion of COVID-19 Phase 2b trial; Dosing expected to begin in second quarter of 2025 Completed enrollment of Phase 1 clinical trial evaluating Company's second-generation oral norovirus vaccine constructs, with topline data expected in mid-2025 New avian influenza vaccine candidate was 100% protective in a ferret challenge model, compared with 0% survival in placebo-treated animals Jeroen Grasman appointed as Chief Financial Officer effective May 19, 2025 Cash, cash equivalents and investments of $41.9 million as of March 31, 2025; Current runway into 2026 Conference call today at 4:30 p.m. ET SOUTH SAN FRANCISCO, Calif., May 13, 2025 (

      5/13/25 4:05:00 PM ET
      $VXRT
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Vaxart to Host First Quarter 2025 Business Update and Financial Results Conference Call on May 13

      Conference call to begin at 4:30 p.m. ET SOUTH SAN FRANCISCO, Calif., May 02, 2025 (GLOBE NEWSWIRE) -- Vaxart, Inc. (NASDAQ:VXRT) today announced it will provide a business update and report financial results for the first quarter ended March 31, 2025, after the market close on Tuesday, May 13, 2025. The Vaxart senior management team will host a conference call on the same day, beginning at 4:30 p.m. ET. The conference call can be accessed using the following information: Webcast: Click hereDate: Tuesday, May 13, 2025 – 4:30 p.m. ETDomestic: (877) 407-0832International: (201) 689-8433Conference ID: 13753354 Investors may submit written questions in advance of the confer

      5/2/25 8:00:00 AM ET
      $VXRT
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Vaxart Provides Business Update and Reports Full Year 2024 Financial Results

      Initiated Phase 1 clinical trial evaluating its second-generation oral norovirus vaccine constructs with topline data expected as early as mid-2025 Continues per protocol follow-up for the COVID-19 Phase 2b 400-person sentinel cohort Cash, cash equivalents and investments of $51.7 million as of December 31, 2024 provides runway through multiple development milestones and into the fourth quarter of 2025 Conference call today at 4:30 p.m. ET SOUTH SAN FRANCISCO, Calif., March 20, 2025 (GLOBE NEWSWIRE) -- Vaxart, Inc. (NASDAQ:VXRT) today announced its business update and financial results for the full year 2024. "Since our founding, Vaxart has been on a mission to transform glo

      3/20/25 4:01:00 PM ET
      $VXRT
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    $VXRT
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • SEC Form SC 13G/A filed by Vaxart Inc (Amendment)

      SC 13G/A - Vaxart, Inc. (0000072444) (Subject)

      2/13/24 5:16:04 PM ET
      $VXRT
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • SEC Form SC 13G filed by Vaxart Inc

      SC 13G - Vaxart, Inc. (0000072444) (Subject)

      1/19/24 4:30:58 PM ET
      $VXRT
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • SEC Form SC 13G filed by Vaxart Inc

      SC 13G - Vaxart, Inc. (0000072444) (Subject)

      2/9/23 11:35:17 AM ET
      $VXRT
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    $VXRT
    Leadership Updates

    Live Leadership Updates

    See more
    • Vaxart Appoints Jeroen Grasman as Chief Financial Officer

      - Mr. Grasman brings over two decades of biotech financial leadership experience - SOUTH SAN FRANCISCO, Calif., May 13, 2025 (GLOBE NEWSWIRE) -- Vaxart, Inc. (NASDAQ:VXRT) today announced the appointment of Jeroen Grasman as its Chief Financial Officer (CFO), effective May 19, 2025. Mr. Grasman succeeds Phillip Lee, who is resigning from his position as CFO for personal reasons. To ensure a smooth transition, Mr. Lee will remain with the Company as a non-executive employee through June 1, 2025. "We are delighted to welcome Jeroen to the Vaxart team," said Steven Lo, Chief Executive Officer of Vaxart. "His extensive financial expertise and proven track record in the biotech sector, includ

      5/13/25 4:01:00 PM ET
      $VXRT
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Vaxart Appoints Seasoned Biotech Executive Kevin Finney to Board of Directors

      Mr. Finney brings 35 years of leadership, operations and corporate development experience SOUTH SAN FRANCISCO, Calif., Jan. 28, 2025 (GLOBE NEWSWIRE) -- Vaxart, Inc. (NASDAQ:VXRT) (the "Company" or "Vaxart") today announced the appointment of Kevin Finney to the Company's Board of Directors, effective today. Mr. Finney is a seasoned healthcare executive and experienced board member who brings decades of industry leadership experience and operational expertise. Mr. Finney will serve as a member of the Audit and Nominating and Governance Committees of the Board. "Kevin adds a wealth of healthcare industry experience spanning executive leadership, governance, operations, and corporate deve

      1/28/25 8:00:00 AM ET
      $VXRT
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Vaxart, Inc. Appoints Steven Lo as President, Chief Executive Officer, and Director

      Michael J. Finney, Ph.D. to Continue as Chairman of the Board of Directors SOUTH SAN FRANCISCO, Calif., March 06, 2024 (GLOBE NEWSWIRE) -- Vaxart, Inc. (NASDAQ:VXRT) (the "Company" or "Vaxart") today announced that it has appointed Steven Lo as President and Chief Executive Officer and a member of the Board of Directors, effective as of March 18, 2024. Mr. Lo is a highly experienced biopharma executive with over 25 years of experience in the healthcare, biotechnology, and pharmaceutical industries, including over 12 years of C-level experience in publicly traded biotech companies. Michael J. Finney, Ph.D. will step down as interim Chief Executive Officer and will continue to serve as Ch

      3/6/24 8:00:00 AM ET
      $VXRT
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    $VXRT
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    See more

    $VXRT
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • President, Chief Exec Officer Lo Steven bought $49,000 worth of shares (100,000 units at $0.49) (SEC Form 4)

      4 - Vaxart, Inc. (0000072444) (Issuer)

      5/19/25 6:49:39 PM ET
      $VXRT
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Director Watson W. Mark bought $13,578 worth of shares (20,000 units at $0.68), increasing direct ownership by 34% to 78,125 units (SEC Form 4)

      4 - Vaxart, Inc. (0000072444) (Issuer)

      6/20/24 6:10:10 AM ET
      $VXRT
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Oppenheimer initiated coverage on Vaxart with a new price target

      Oppenheimer initiated coverage of Vaxart with a rating of Outperform and set a new price target of $4.00

      8/15/24 7:45:56 AM ET
      $VXRT
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Jefferies resumed coverage on Vaxart with a new price target

      Jefferies resumed coverage of Vaxart with a rating of Buy and set a new price target of $12.00 from $13.00 previously

      12/29/21 7:23:57 AM ET
      $VXRT
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Cantor Fitzgerald initiated coverage on Vaxart with a new price target

      Cantor Fitzgerald initiated coverage of Vaxart with a rating of Overweight and set a new price target of $15.00

      11/2/21 7:42:45 AM ET
      $VXRT
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care